Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Reference Guide
  /  
3-MT
Sign up free to test for 
3-MT
.
One login for 30+ lab companies.

3-Methoxytyramine

3-Methoxytyramine (3-MT) is a metabolite of the neurotransmitter dopamine and serves as a significant biomarker in various medical contexts.  

In neuroblastoma, a childhood cancer, elevated levels of urinary 3-MT at diagnosis are indicative of high-risk disease and poor prognosis.  This elevation reflects increased MYC activity and MYCN amplification in tumor cells, both of which drive tumor growth and progression. 

High 3-MT levels correlate with a specific gene expression pattern linked to MYC activity, known as the 3-MT gene signature, which predicts poor survival even in low-risk patients. 

Elevated 3-MT levels have also been observed in patients with pheochromocytoma, making it a useful marker for diagnosing and monitoring this adrenal gland tumor.

Measuring urinary 3-MT provides a non-invasive method to assess MYC activity, aiding in risk assessment and potentially guiding treatment strategies. 

Additionally, 3-MT's role extends beyond being a mere dopamine byproduct; it acts as a neuromodulator influencing behavior through the trace amine-associated receptor 1 (TAAR1), with implications for conditions like Parkinson's disease and schizophrenia. 

What is 3-MT?  [18.] 

3-Methoxytyramine (3MT) is a biomarker for MYC activity and poor prognosis in neuroblastoma, a type of childhood cancer. 

It is a metabolite of the neurotransmitter dopamine, produced by the enzyme dopamine beta-hydroxylase. 

Elevated levels of 3MT in urine at the time of neuroblastoma diagnosis are associated with high-risk disease and poor clinical outcome.  These high urinary 3MT levels reflect increased MYC activity and MYCN amplification in the tumor cells. MYC and MYCN are oncogenes that drive tumor growth and progression when overexpressed.

A gene signature derived from the differentially expressed genes associated with high 3MT levels can predict poor survival, even in low-risk neuroblastoma patients.  

Tumors from patients with elevated urinary 3MT show strong MYCN protein expression but weak dopamine beta-hydroxylase expression, linking MYC activity to catecholamine biosynthesis and 3MT levels. 

Measuring urinary 3MT at diagnosis can assist in assessing risk and prognosis in neuroblastoma patients. 

In summary, 3MT is a promising biomarker that reflects the underlying biology of high-risk neuroblastoma driven by MYC/MYCN oncogene activity. Elevated urinary 3MT levels indicate poor prognosis, making it a clinically useful marker for risk stratification.

The Relationship Between The MYC Gene and Protein, and 3-MT Levels  [18.] 

Elevated levels of 3-MT in urine are associated with poor prognosis in neuroblastoma patients, reflecting increased MYC activity in tumors.  

This was confirmed in both retrospective and prospective patient cohorts, where high urinary 3-MT levels correlated with a specific gene expression pattern, termed the 3-MT gene signature. This signature includes eight differentially expressed genes that predict poor clinical outcomes and are linked to MYC activity.

The MYC gene encodes a transcription factor that regulates cell growth, proliferation, and apoptosis.  MYC proteins bind to DNA, influencing the expression of numerous genes essential for cell cycle progression and metabolism. 

In neuroblastoma, high MYC activity leads to more aggressive tumor behavior and poorer prognosis.  

The study by Verly et. al. found that tumors with elevated urinary 3-MT levels exhibited strong MYCN (a MYC gene family member) staining and weak dopamine β-hydroxylase expression, linking MYC activity to altered catecholamine biosynthesis.  [18.] 

Thus, measuring urinary 3-MT levels can provide a non-invasive method to assess MYC activity in neuroblastoma, aiding in risk assessment and potentially guiding treatment strategies that target MYC signaling pathways.

Biochemistry and Physiology of 3-MT

The biochemistry and physiology of 3-MT (3-methoxytyramine) are closely tied to the metabolism of catecholamines, particularly dopamine, in the body.

Synthesis and Metabolism of 3-MT  [17.] 

3-MT is formed through the O-methylation of dopamine by the enzyme catechol-O-methyltransferase (COMT). This process occurs primarily in the extraneuronal spaces of various tissues, including the brain, adrenal glands, and other organs. 

The resulting 3-MT is then further metabolized by monoamine oxidase (MAO) enzymes, ultimately leading to the formation of vanillylmandelic acid (VMA), which is excreted in urine.

Functions of 3-MT in the Body  [17.] 

Recent research reveals that 3-methoxytyramine (3-MT), a major metabolite of dopamine (DA) that was once thought to be biologically inactive, acts as a neuromodulator to independently influence behavior through the trace amine-associated receptor 1 (TAAR1). 

In one study 3-MT was found to induce complex abnormal movements and behaviors in dopamine-deficient and normal mice.  These findings highlight 3-MT's role beyond being a mere dopamine byproduct, suggesting it impacts movement control and signaling pathways in the brain.

The study suggests that 3-MT's neuromodulatory role, facilitated by TAAR1 activation, could be significant in conditions with abnormal dopaminergic transmission such as Parkinson's disease and schizophrenia.  

Elevated 3-MT levels might contribute to side effects in Parkinson's treatment and could be implicated in schizophrenia's pathophysiology.

Diseases and Conditions Associated with Altered 3-MT Levels

Elevated levels of 3-MT have been observed in patients with pheochromocytoma, a rare tumor of the adrenal gland that secretes excessive amounts of catecholamines.  In these cases, 3-MT measurement can aid in the diagnosis and monitoring of the disease.  [1.] 

Additionally, increased 3-MT levels have been reported in neuroblastoma, a cancer of the sympathetic nervous system that primarily affects children.  [18.] 

Alterations in 3-MT levels have also been implicated in neurological disorders, such as Parkinson's disease and schizophrenia, where dopaminergic dysfunction plays a role.  However, the clinical utility of 3-MT as a biomarker in these conditions requires further investigation.

Symptoms of Altered Dopamine Levels

Increased or decreased levels of 3-MT may correlate with symptoms of dopamine excess and deficiency.

Symptoms of Excessive Dopamine

Symptoms of excessive dopamine can have various manifestations, including:

Physiological Symptoms of Excessive Catecholamine Production  [15., 16.] 

  • Hypertension: high blood pressure due to excessive catecholamine production
  • Tachycardia: rapid heart rate
  • Palpitations: irregular heartbeats
  • Sweating and Flushing: due to increased catecholamine levels
  • Headaches: often severe and sudden due to blood pressure spikes
  • Vasoconstriction causing poor peripheral circulation: as a result of vasoconstriction, there can be a decrease in blood flow to peripheral areas, potentially leading to complications such as gangrene in severe cases.

Impulsivity and Poor Impulse Control  [14.] 

  • Acting rashly without considering consequences

  • Difficulty controlling urges or delaying gratification

  • Engaging in risky behaviors like gambling, hypersexuality, etc.

Aggression and Agitation  [14., 16.] 

  • Increased aggressive and violent tendencies
  • Irritability and quick temper
  • Hostility towards others

Hyperactivity and Restlessness  [16.] 

  • Feeling overly energetic and restless
  • Inability to sit still or remain calm
  • Fidgeting and constant movement; in some cases of excessive use of L-DOPA, a Parkinson’s medication, abnormal and involuntary movements may be seen.  

Mania and Psychosis  [16.] 

  • Symptoms of mania like euphoria, grandiose thinking
  • Hallucinations and delusions
  • Paranoia and disordered thinking

Sleep Disturbances  [8.] 

  • Insomnia and difficulty falling/staying asleep
  • Reduced need for sleep during manic episodes

Addiction and Compulsive Behaviors  [14.] 

  • Increased risk of addiction and substance abuse
  • Compulsive behaviors like gambling, shopping, etc.
  • Constantly seeking dopamine-releasing activities

Symptoms of Low Dopamine

Low dopamine may manifest in physical or mental symptoms.  Of note, Parkinson’s disease is characterized by low levels of dopamine.

An age-related decline in available dopamine has also been noted.  [11.] 

Parkinson’s Disease  [4., 16.] 

  • Motor Symptoms: The primary motor symptoms of Parkinson's disease are due to the degeneration of dopaminergic neurons in the caudate nucleus. These include tremors, rigidity, bradykinesia (slowness of movement), and postural instability.
  • Non-Motor Symptoms: These can include mood disorders, sleep disturbances, cognitive impairments, and gastrointestinal dysfunctions.

Hypotension and Cardiac Issues  [16.] 

  • Low dopamine levels can lead to low blood pressure (hypotension) and low heart rate, necessitating the use of dopamine as a peripheral vasostimulant in clinical settings to treat these conditions.
  • Symptoms: Dizziness, fainting, and inadequate blood flow to organs, potentially leading to organ dysfunction.

Neuropsychiatric Symptoms  [4., 16.] 

  • Dopamine's central role in the mesocorticolimbic pathway impacts reward-seeking behavior and cognitive functions.
  • Symptoms of Low Dopamine in the CNS:some text
    • Depression
    • Lack of motivation
    • Fatigue and excessive daytime sleepiness
    • Decreased ability to focus and concentrate
    • Anhedonia (inability to feel pleasure)

Cognitive Symptoms  [4., 16.] 

  • Attention deficit disorders can be associated with low dopamine levels affecting focus and executive function.

Hormonal and Endocrine Effects  [4.] 

  • Hyperprolactinemia, leading to symptoms such as amenorrhea, loss of libido, and gynecomastia.

Potential Withdrawal Symptoms:  [4., 16.] 

  • Cessation of dopamine agonists or mimetics can lead to dopamine agonist withdrawal syndrome.
  • Symptoms: Anxiety, depression, panic attacks, fatigue, hypotension, nausea, irritability, and suicidal ideations.

Laboratory Testing for 3-MT

3-Methoxytyramine Lab Test Information, Sample Collection and Preparation

The measurement of 3-MT typically involves the collection of urine or plasma samples from patients.  Blood testing requires a venipuncture.  Urine samples are typically collected over 24 hours.  

This test may be run alone, or as part of a panel to assess levels of metanephrines and other catecholamine-related compounds.  

It is essential to consult with the ordering provider prior to sample collection, as some special preparation may be required.  

Interpretation of 3-MT Test Results

3-MT Optimal Results

The interpretation of 3-MT test results requires careful consideration of various factors, including age, gender, and specific clinical context.  Reference ranges and cut-off values may vary depending on the analytical method used and the population studied. 

As a point of reference, one lab reports optimal levels of 3-MT in a 24 hour urine sample as: 122-278 nmol/g creatinine.  [12.] 

Excessively high or low levels may indicate an issue with dopamine metabolism and require further assessment.  

Clinical Significance of Elevated 3-MT Levels

Elevated 3-MT levels, particularly in the setting of symptoms of high dopamine, warrant further assessment.  

Elevated 3-MT levels may be associated with neuroblastoma in children, pheochromocytoma,  other dopamine-producing tumors, or in schizophrenia.

Clinical Significance of Decreased 3-MT Levels

 Decreased 3-MT levels may be associated with Parkinson’s disease or ADHD.  [5.] 

3-Methoxytyramine Related Biomarkers

In addition to 3-MT (3-methoxytyramine), several other biomarkers are closely related and often measured in conjunction to provide a comprehensive assessment of catecholamine metabolism and associated disorders.

Catecholamines

Catecholamines including dopamine, norepinephrine, and epinephrine, are the primary neurotransmitters and hormones involved in the sympathetic nervous system. 

Measurement of these compounds and their metabolites can provide insights into the underlying pathophysiology of various conditions such as pheochromocytoma, neuroblastoma, and cardiovascular disorders.

Metanephrines

Metanephrines including normetanephrine and metanephrine are metabolites of norepinephrine and epinephrine, respectively. 

Elevated levels of these biomarkers are commonly observed in pheochromocytoma and paraganglioma, making them valuable diagnostic tools for these conditions.

Vanillylmandelic Acid (VMA) and Homovanillic Acid (HVA)

VMA and HVA are end-products of catecholamine metabolism. While their clinical utility has been somewhat superseded by more specific biomarkers, they can still provide complementary information, particularly in the evaluation of neuroblastoma and certain neurological disorders.

Natural Ways to Optimize Dopamine Levels

A healthy diet and lifestyle are foundational for healthy dopamine levels.  

Get Sufficient Sleep Regularly  [19., 20.] 

Lack of sleep can disrupt natural dopamine rhythms and reduce dopamine sensitivity in the brain, leading to excessive sleepiness and reduced alertness.

Establishing a consistent sleep schedule and practicing good sleep hygiene can help regulate dopamine levels.

Listen to Music You Love  [13.] 

Research shows that listening to enjoyable music can stimulate the release of dopamine in the brain.

Eat Healthy, Whole Foods

Consume foods rich in the amino acid tyrosine, a precursor for dopamine production, such as dairy products, eggs, beans, whole grains, beef, lamb, chicken, fish, and nuts.  [9.] 

Combine them with ample fruits and vegetables for their high antioxidant quantity.  

Limit intake of saturated fats, as diets high in saturated fat may dampen dopamine signaling and release.  [2.] 

Exercise

Regular physical activity has been shown to increase dopamine levels in the brain.  For example, individuals who engaged in a daily yoga practice over 3 months showed a significant increase in dopamine levels.  [11.] 

Exercise can improve mood and motivation, which are influenced by dopamine.

Increase Positive Social Interactions 

Positive social interactions and feelings of social reward can stimulate dopamine release in the brain's reward system.  [7.] 

Relax and Reduce Stress

Practicing mindfulness meditation, deep breathing, massage, etc. can support healthy dopamine levels.  [6.] 

Chronic stress can lead to dysregulation of dopamine levels and impaired dopamine signaling in the brain.  [3.] 

In particular, meditation has been found to increase dopamine levels in the brain, potentially improving focus and reducing stress.  [6.] 

Limit Your Intake of Processed Foods and Avoid Sugar

Processed foods often contain high levels of saturated fats, which may disrupt dopamine signaling and release.  [2.] 

Dietary sugar also has strong effects on the dopamine system.  Eating sugar triggers dopamine release, reinforcing sugar consumption.  Over time, high sugar diets diminish taste sensitivity and weaken dopamine-related satiety signals, leading to overeating and weight gain.  [10.] 

Order 3-MT Testing

Click here to compare testing options and order testing to assess dopamine processing.  

What's 
3-MT
?
If Your Levels Are High
Symptoms of High Levels
If Your Levels are Low
Symptoms of Low Levels
See References

[1.] 3MT - Overview: 3-Methoxytyramine, 24 Hour, Urine. @mayocliniclabs. Published 2019. Accessed June 7, 2024. https://www.mayocliniclabs.com/test-catalog/overview/65157

[2.] Barnes CN, Wallace CW, Jacobowitz BS, Fordahl SC. Reduced phasic dopamine release and slowed dopamine uptake occur in the nucleus accumbens after a diet high in saturated but not unsaturated fat. Nutr Neurosci. 2022 Jan;25(1):33-45. doi: 10.1080/1028415X.2019.1707421. Epub 2020 Jan 9. PMID: 31914869; PMCID: PMC7343597.

[3.] Bloomfield MA, McCutcheon RA, Kempton M, Freeman TP, Howes O. The effects of psychosocial stress on dopaminergic function and the acute stress response. Elife. 2019 Nov 12;8:e46797. doi: 10.7554/eLife.46797. PMID: 31711569; PMCID: PMC6850765.

[4.] Juárez Olguín H, Calderón Guzmán D, Hernández García E, Barragán Mejía G. The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress. Oxid Med Cell Longev. 2016;2016:9730467. doi: 10.1155/2016/9730467. Epub 2015 Dec 6. PMID: 26770661; PMCID: PMC4684895.

[5.] khan M zahid, nawaz W. The emerging roles of human trace amines and human trace amine-associated receptors (hTAARs) in central nervous system. Biomedicine & Pharmacotherapy. 2016;83:439-449. doi:https://doi.org/10.1016/j.biopha.2016.07.002

[6.] Kjaer TW, Bertelsen C, Piccini P, Brooks D, Alving J, Lou HC. Increased dopamine tone during meditation-induced change of consciousness. Brain Res Cogn Brain Res. 2002 Apr;13(2):255-9. doi: 10.1016/s0926-6410(01)00106-9. PMID: 11958969.

[7.] Krach S, Paulus FM, Bodden M, Kircher T. The rewarding nature of social interactions. Front Behav Neurosci. 2010 May 28;4:22. doi: 10.3389/fnbeh.2010.00022. PMID: 20577590; PMCID: PMC2889690.

[8.] Li L, Zhao Z, Ma J, et al. Elevated Plasma Melatonin Levels Are Correlated With the Non-motor Symptoms in Parkinson’s Disease: A Cross-Sectional Study. Frontiers in Neuroscience. 2020;14. doi:https://doi.org/10.3389/fnins.2020.00505

[9.] Lou HC. Dopamine precursors and brain function in phenylalanine hydroxylase deficiency. Acta Paediatr Suppl. 1994 Dec;407:86-8. doi: 10.1111/j.1651-2227.1994.tb13461.x. PMID: 7766968.

[10.] May CE, Rosander J, Gottfried J, Dennis E, Dus M. Dietary sugar inhibits satiation by decreasing the central processing of sweet taste. Ramaswami M, Dulac C, Ramaswami M, Keene AC, eds. eLife. 2020;9:e54530. doi:https://doi.org/10.7554/eLife.54530

[11.] Pal R, Singh SN, Chatterjee A, Saha M. Age-related changes in cardiovascular system, autonomic functions, and levels of BDNF of healthy active males: role of yogic practice. Age (Dordr). 2014;36(4):9683. doi: 10.1007/s11357-014-9683-7. Epub 2014 Jul 11. PMID: 25012275; PMCID: PMC4150910.

[12.] Rupa Health.  Comprehensive Neurotransmitters Sample Report.pdf. Google Docs. Accessed June 7, 2024. https://drive.google.com/file/d/1Zk2T30HvTiA7EpPoqfNbaCBs_fYn69MR/view

[13.] Salimpoor, V., Benovoy, M., Larcher, K. et al. Anatomically distinct dopamine release during anticipation and experience of peak emotion to music. Nat Neurosci 14, 257–262 (2011). https://doi.org/10.1038/nn.2726

[14.] Seo D, Patrick CJ, Kennealy PJ. Role of Serotonin and Dopamine System Interactions in the Neurobiology of Impulsive Aggression and its Comorbidity with other Clinical Disorders. Aggress Violent Behav. 2008 Oct;13(5):383-395. doi: 10.1016/j.avb.2008.06.003. PMID: 19802333; PMCID: PMC2612120.

[15.] Smy L, Kushnir MM, Frank EL. A high sensitivity LC-MS/MS method for measurement of 3-methoxytyramine in plasma and associations between 3-methoxytyramine, metanephrines, and dopamine. J Mass Spectrom Adv Clin Lab. 2021 Aug 5;21:19-26. doi: 10.1016/j.jmsacl.2021.08.001. PMID: 34820673; PMCID: PMC8601001.

[16.] Sonne J, Goyal A, Lopez-Ojeda W. Dopamine. [Updated 2023 Jul 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535451/

[17.] Sotnikova TD, Beaulieu JM, Espinoza S, Masri B, Zhang X, Salahpour A, Barak LS, Caron MG, Gainetdinov RR. The dopamine metabolite 3-methoxytyramine is a neuromodulator. PLoS One. 2010 Oct 18;5(10):e13452. doi: 10.1371/journal.pone.0013452. Erratum in: PLoS One. 2010;5(10) doi: 10.1371/annotation/a2019934-b1cc-4781-80cb-9e09fc7ff6dc. PMID: 20976142; PMCID: PMC2956650.

[18.] Verly IRN, Matser YAH, Leen R, Meinsma R, Fiocco M, Koster J, Volckmann R, Savci-Heijink D, Cangemi G, Barco S, Valentijn LJ, Tytgat GAM, van Kuilenburg ABP. Urinary 3-Methoxytyramine Is a Biomarker for MYC Activity in Patients With Neuroblastoma. JCO Precis Oncol. 2022 Jan;6:e2000447. doi: 10.1200/PO.20.00447. PMID: 35085004; PMCID: PMC8830522.

[19.] Volkow ND, Tomasi D, Wang GJ, Telang F, Fowler JS, Logan J, Benveniste H, Kim R, Thanos PK, Ferré S. Evidence that sleep deprivation downregulates dopamine D2R in ventral striatum in the human brain. J Neurosci. 2012 May 9;32(19):6711-7. doi: 10.1523/JNEUROSCI.0045-12.2012. PMID: 22573693; PMCID: PMC3433285.

[20.] Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F, Fowler JS, Zhu W, Logan J, Ma Y, Pradhan K, Wong C, Swanson JM. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA. 2009 Sep 9;302(10):1084-91. doi: 10.1001/jama.2009.1308. Erratum in: JAMA. 2009 Oct 7;302(13):1420. PMID: 19738093; PMCID: PMC2958516.

Test for

3-Methoxytyramine

Order, track, and receive results from 30+ labs in one place.